Bottom line
Is MSVOX a good fund? The bottom line
MSVOX is the Class R6 share class of Vitality Portfolio, a managed other mutual fund from Morgan Stanley.
It charges 0.9% — about $90 a year on every $10,000 invested, cheaper than 55% of other funds we track.
It returned +15.0% over one year (as of Dec 31, 2025, per its prospectus).
What stands out
- No front-end sales load
Updated Nov 19, 2026
What MSVOX invests in
The Vitality Portfolio (the Fund) seeks long-term capital appreciation.
Under normal market conditions, the Adviser seeks to achieve the Funds investment objective by investing primarily in securities of companies located in the United States that are principally engaged in the discovery, development, production, or distribution of products or services related to advances in healthcare. These companies include, but are not limited to, biotechnology, pharmaceuticals, medical equipment and supplies, healthcare technology, healthcare providers and services, and life sciences tools and services. The Fund may also allocate to industries related to the healthcare industry, but are not primarily engaged in the scientific advancement of healthcare. The allocation among these areas will vary depending on the relative potential the Adviser sees within each area and the outlook for the overall healthcare sector. ? The Adviser emphasizes a bottom-up stock selection…
From the fund's prospectus (filed Apr 30, 2026).
MSVOX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| MSVOX | +15.0% | — | — |
| Other median | +9.2% | +4.9% | +5.3% |
Source: Fund prospectus, as of Dec 31, 2025
What MSVOX costs
On a $10,000 investment, MSVOX's 0.9% expense ratio costs about $90 a year. The prospectus estimates $10,008 in total costs over 10 years (assuming 5% annual returns). The median other fund charges 0.95%.